Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024
February 02 2024 - 7:00AM
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field
of cellular metabolism pioneering therapies for rare diseases,
today announced the company will host a conference call and live
webcast on Thursday, February 15, 2024, at 8:00 a.m. ET to report
its fourth quarter and year end 2023 financial results and other
business highlights.
A live webcast of the presentation can be accessed under "Events
& Presentations" in the Investors section of the company's
website at www.agios.com. A replay of the webcast will be archived
on the company’s website for at least two weeks following the
presentation.
About AgiosAgios is the pioneering leader in PK
activation and is dedicated to developing and delivering
transformative therapies for patients living with rare diseases. In
the U.S., Agios markets a first-in-class pyruvate kinase (PK)
activator for adults with PK deficiency, the first
disease-modifying therapy for this rare, lifelong, debilitating
hemolytic anemia. Building on the company's leadership in the field
of cellular metabolism and rare hematologic diseases, Agios is
advancing a robust clinical pipeline of investigational medicines
with programs in alpha- and beta-thalassemia, sickle cell disease,
pediatric PK deficiency and MDS-associated anemia. In addition to
its clinical pipeline, Agios has TMPRSS6 siRNA as a potential
treatment for polycythemia vera, a PAH stabilizer in preclinical
development as a potential treatment for phenylketonuria (PKU), and
deep scientific expertise in classical hematology. For more
information, please visit the company’s website at
www.agios.com.
Contacts:
Investor ContactChris Taylor, VP, Investor
Relations and Corporate CommunicationsAgios
PharmaceuticalsIR@agios.com
Media Contact Dan Budwick1AB dan@1abmedia.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Apr 2023 to Apr 2024